Potential T-cell Lymphoma Treatment Withdrawn During Phase III Testing

Following an interim look at data from an ongoing phase III trial, Takeda Oncology has ended the development of alisertib as a possible treatment for patients with peripheral T-cell lymphoma (PTCL).

Alisertib, previously known as MLN8237, was being studied as a kinase inhibitor in PTCL patients that could stop cancer cell proliferation. The phase III trial was investigating the compound's ability to do better than the standard of care in these patients with regard to progression-free survival, or the length of time following treatment before the disease began to progress again.

Alisertib was previously being developed by Millennium Pharmaceuticals before that company was bought by Takeda.

This doesn't mean the end of alisertib, as there is also an ongoing phase II trial against small cell lung cancer, and even earlier-stage trials against other non-Hodgkin lymphomas as well as some solid tumor cancers.

"While we are disappointed that alisertib will not be further investigated for relapsed or refractory peripheral T-cell lymphoma, we are optimistic about alisertib's clinical development program in small cell lung cancer," said Takeda Oncology chief Michael Vasconcelles. "The randomized Phase II study of alisertib in small cell lung cancer will continue as planned and is currently underway."

Source: FierceBiotech

lymphoma roundup

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...